P1-236: The study of MicRNA 107 and BACE1 mRNA gene expression in peripheral blood and cerebrospinal fluid of Alzheimer's disease

2013 ◽  
Vol 9 ◽  
pp. P239-P239
Author(s):  
Tao Wang ◽  
Huafang Li ◽  
Ning Su ◽  
Yuanyuan Liu ◽  
Yan Cheng ◽  
...  
2017 ◽  
Vol 17 (3) ◽  
pp. 117-125 ◽  
Author(s):  
Emma Kamelia ◽  
Andi Asadul Isl ◽  
Mochammad Hatta ◽  
Cahyono Kaelan ◽  
Ilhamjaya Patellongi ◽  
...  

Author(s):  
Emma Kamelia ◽  
Andi Asadul Islam ◽  
Mochammad Hatta ◽  
Cahyono Kaelan ◽  
Ilhamjaya Patellongi

 Objective: The objective of this study is to analyze caspase-3 mRNA gene expression in a Wistar rat model of Alzheimer’s disease (AD) treated with Musa paradisiaca L. (MPL) ethanol extract or banana extract (BE)Methods: MPL was evaluated for its effect on the caspase-3 mRNA gene expression of rat amyloid beta (Aβ) induced, an AD model. Each model included twenty Wistar rats were randomized into five groups: K0, without AD induction and no BE; K1, AD induction and no BE; K2, AD induction+BE 250 mg/kg body weight (BW); K3, AD induction+BE 500 mg/kg; and K4, AD induction+BE 1000 mg/kg. AD induction was performed by Aβ1-42 (0.2 ug) injection at the intracerebroventricular area. mRNA caspase-3 level measurements were performed by real time-polymerase chain reaction.Results: Paired t-test analysis showed no significant differences of caspase-3 mRNA level before Aβ induction among five groups (p>0.05). At 6 weeks post-Aβ induction, there was significantly increased caspase-3 mRNA in all groups except K0 (p<0.05). Notably, after 3 weeks of BE administration, caspase-3 mRNA expression was significantly decreased in all BE-treated groups; in the K1 placebo group, caspase-3 mRNA expression increased. The maximum decreased caspase-3 mRNA expression was in group K4 (-BE 1000 mg/kg BW), and the minimum was in group K2 (-BE 250 mg/kg BW).Conclusion: The results revealed that the ethanolic extract of MPL fruit could decrease caspase-3 mRNA gene expression in AD rat.


2021 ◽  
pp. 1-8
Author(s):  
Marcella Reale ◽  
Claudia Carrarini ◽  
Mirella Russo ◽  
Fedele Dono ◽  
Laura Ferri ◽  
...  

Background: Central nervous system disruption of cholinergic (ACh) signaling, which plays a major role in cognitive processes, is well documented in dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD). The expression of muscarinic ACh receptors type 1 and 4 (CHRM1 and CHRM4) has been reported to be altered in the brain of DLB patients. Objective: We aim to assess the peripheral gene expression of CHRM1 and 4 in DLB as a possible marker as compared to AD and healthy control (HC) subjects. Methods: Peripheral blood mononuclear cells were collected from 21 DLB, 13 AD, and 8 HC matched subjects. RT-PCR was performed to estimate gene expression of CHRM1 and CHRM4. Results: Peripheral CHRM1 expression was higher and CHRM4 was lower in DLB and AD compared to HC, whereas both CHRM1 and CHRM4 levels were higher in AD compared to DLB patients. Receiver operating characteristics curves, with logistic regression analysis, showed that combining peripheral CHRM1 and CHRM4 levels, DLB and AD subjects were classified with an accuracy of 76.0%. Conclusion: Alterations of peripheral CHRM1 and CHRM4 was found in both AD and DLB patients as compared to HC. CHRM1 and CHRM4 gene expression resulted to be lower in DLB patients compared to AD. In the future, peripheral CHRM expression could be studied as a possible marker of neurodegenerative conditions associated with cholinergic deficit and a possible marker of response to acetylcholinesterase inhibitors.


2021 ◽  
Author(s):  
Andrew Ni ◽  
Amish Sethi ◽  

AbstractDetecting Alzheimer’s Disease (AD) at the earliest possible stage is key in advancing AD prevention and treatment but is challenged by normal aging processes in addition to other confounding neurodegenerative diseases. Recent genome-wide association studies (GWAS) have identified associated alleles, but it has been difficult to transition from non-coding genetic variants to underlying mechanisms of AD. Here, we sought to reveal functional genetic variants and diagnostic biomarkers underlying AD using machine learning techniques. We first developed a Random Forest (RF) classifier using microarray gene expression data sampled from the peripheral blood of 744 participants in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort. After initial feature selection, 5-fold cross-validation of the 100-gene RF classifier achieved an accuracy of 99.04%. The high accuracy of the RF classifier supports the possibility of a powerful and minimally invasive tool for screening of AD. Next, unsupervised clustering was used to validate and identify relationships among differentially expressed genes (DEGs) the RF selected revealing 3 distinct AD clusters. Results suggest downregulation of global sulfatase and oxidoreductase activities in AD through mutations in SUMF1 and SMOX respectively. Then, we used Greedy Fast Causal Inference (GFCI) to find potential causes of AD within DEGs. In the causal graph, HLA-DPB1 and CYP4A11 emerge as hub genes, furthering the discussion of the immune system’s role in AD. Finally, we used Gene Set Enrichment Analysis (GSEA) to determine the biological pathways and processes underlying the DEGs that were highly correlated with AD. Cell activation in the immune system, glycosaminoglycan (GAG) binding, vascular dysfunction, oxidative stress, and the neuronal apoptotic process were revealed to be significantly enriched in AD. This study further advances the possibility of low-cost and noninvasive genetic screening for AD while also providing potential gene targets for further experimentation.


2016 ◽  
Vol 31 (2) ◽  
pp. 317-317
Author(s):  
Francesca Montarolo ◽  
Simona Perga ◽  
Serena Martire ◽  
De’sire’e Nicole Navone ◽  
Alberto Marchet ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document